Murasaki M,Miura S. .1992 .The futureof 5-HT-1A receptor agonists. (Arylpiperazinederivatives). Prog NeuropsychopharmacoiBioiPsych, 16 : 6833-45.
. .Serotoninand anxiety:a reviewof currentresearchand clinicalimplicationsJ. CPSP\^^\ 9, (8) : 384-93.
McKearney JW .1989 .Serotonin-anatgonisteffectsof 1- (1-naphthylp)iperazineon operantbehaviorofsquirrel monkeys. NeuropharmacoiOgy, 28 : 817-21.
.1995 .BrileyM. In vitro and in vivo activityof 1-(1- naphthyl)piperazinaetterminal5-HT autoreceptorisn guina pig brain. Naunyn-Schmiedeberg's Arch Pharma, 351 : 377-84.
Hanson HM . .. Psychopharmacoiogy^lT, 55 : 27-33.
Simansky KJ,Schechter LE .1988 .Properties of some 1- arylpiperazineass antagonistsofstereotypedbehaviors mediatedby centralserotonergic receptors in rodents. JPharma Exp Ther, 247 : 1073-81.
Lucki I . .Differentialctionsofserotonin antagonistsin two behavioralmodelsof sero-. , : .
.1996 .Roleofhippocampa5l-HT-1A receptorson elevatedplus maze explorationaftera singlerestraintexperience. BehavBrainBes, 77 : 215-8.
. .Adaptationoffemale ratstostress:shifttomalepatternby inhibitionofcorticosteronesynthesis. , 458 : 339-47.
Haleem DJ .1996 .. BatoolF. Regionallyspecificeffectsof diazepamon brainserotoninmetabolis min rats:sustainedeffecftollowingrepeatedadministrationL.ifeSci, 59(15) : PL239-PL46.
Ortman R. .1985 .The 5-HT syndrome and thedrug discrimination paradigm in rats: Applicationin behavioral studies on thecentral5-HT system. Pharmacopsychiatry, 18 : 198-201.
Lyon RA .1986 .5-HT-1 and 5-HT-2 binding characteristicsof some quipazineanaloguesJ. MedChem, 29 : 2375-80.
Wedenberg ML .1989 .AlheniusS. Effectof8-OHDPAT on motor activityin therat. Pharma Biochem Behav, 32 : 797-800.
Marcou M,Dourish CT,Curzon G . .Single administrationof5-HT-1A agonistsdecreases5-HT-1A presynaptic,butnot postsynapticreceptor-mediated response: relationshipto antidepressant-likaection.. , : .
Lucki I,Ward HR,Frazer A . .Effecotfm-CPP andTFMPP on locomotoractivityJ. PharmaExp TherV&&\, 249 : 155-64.
Green AR,Guy AP,Gardner OR .1984 .The behavioraelffects of RU-24969, a suggested5-HT-1 receptoragonistin rodentsand theeffecton thebehaviorof treatment withantidepressantsN. europharmacology, 23 : 655-61.
Lowe JA,Seegar TF,Howard HR,Seymour PA,Heyn JH .1991 .-Naphthylpiperazindeerivativesas potentialatypicalanti-psychoticagents. J Med Chem, 34 : 1860-66.
Fernandez AG,Palacios JM .1996 .Effectsof 5-HT-4 receptorantagonistosn ratbehaviorin theelevatedplus-mazetest. EurJPharma, 309 : 219-22.
.1993 .-HT drugs in animalmodels ofanxiety. Psychopharmacology, 109 : 338-45.
.1996 .-Hydroxytryptamine-interactindgrugs in animalmodels of anxietydisorders: More than30 yearsofresearch. JPharma Exp Ther, 65 : 319-95.
.1993 .-HT drugs in animalmodels ofanxiety. Psychopharmacology, 112 : 13-21.
.1986 .Substitutepdhenylpiperazineass serotonin agonists: structuraldeterminantsof potency and interactionwith receptor subtypes. Psychopharma Bull, 22(3) : 825-8.
.1988 .Evidencethatm-CPP may have behavioraelffectmsediatedby central5-HT-1C receptors. BrJPharma, 94 : 137-47.
Cohen ML .1983 .FullerRW. Antagonismof vascularserotonin receptorsby m-chlorophenylpiperazinaend mtrifluoromethylpiperazLinifeS. ci, 32 : 711-8.
. .- HT uptakeblocker,citalopramo,n thesensitivityo,f5- HT autoreceptorsE: lectrophysiologicastludiesin the ratbrain. Naunyn-Schmiedeberg'sArch/%W771986;, 333 : 342-8.
Hamon M,Adrien J .1988 .Alterationsof centralserotonin and dopamine turnoverin ratstreatedwith ipsapironeand other5- HT-1A agonistswithpotentiaalnxiolyticproperties. J Pharma Exp Ther, 246 : 745-52.
Sharp T,Hjorth S,Grahame-Smith DG .1989 .Pharmacologicalcharacterizationof 8-OH-DPATinduced inhibitionofrathippocampal5-HT releasein vivo as measuredby microdialysis. BrJPharma, 98 : 989-97.
.1986 .-HT-1Aselectivedrugs on the 5-HT behavioralsyndrome. PharmaBiochem Behav, 24 : 1513-19.
Yocca FD .1990 .Neurochemistryand neurophysiologyof buspirone and gepirone interactionsat presynaptic and postsynaptic5-HT-1A receptors. Psychopharmacology, 10(3) : 68-125.
.1988 .-HT-1A receptoragonist,8- OH-DPAT, preferentiallayctivatescellbody 5-HT autoreceptorsin theratbrain in vivo. Naunyn-Schmiedeberg'sArch Pharma, 338 : 463-71.
VanderMaelen CP,Wilderman RC,Pater son LA .1986 .Inhibitionof serotonergicdorsalrapheneurons by systemicand iontophoreticadministrationof buspirone,a non-benzodiazepineanxiolyticdrug. EurJ Pharma, 129 : 123-30.
.1988 .Region-selective effectbsy 8-OH-DPAT on braindopaminesynthesisin vivo. Neurochemlnt, 13 : 80.
.1989 .Effectsof buspirone and its metabolite1-(2-pyrimidinyl) piperazine, on brain monoaminesand theirmetaboliteins rats. JPharma Exp Ther, 248 : 50-6.
Suzuki M .1995 .MatsudaT, Asano S, SomboonthumP, Takuma ofm-CPP and TFMPP in animalmodelsare opposed K, Baba A. Increase of noradrenalinereleasein the by 5-HT-1C receptorantagonistsE. urJPharma 1989; 164: hypothalamuosffreelymoving ratby postsynaptic5- 445-54. HT-1A receptoractivationB. rJPharma, 115 : 703-11.
Mason NR,Snoddy HD,Perry KW .1986 .-(1-Naphthylp)iperazine,acentralserotoninagonist. PesCommun Chem Path Pharma, 51 : 37-45.
Snoddy HD,Mason NR .1978 .m-trifluoromethylphenpyiple)razine on 3H-serotonin binding to membranesfrom ratbrain in vitro. EurJPharma, 52 : 11-6.
Suwabe A,Kubota M,Niwa M,Kobayashi K,Kanba S. Effecotfa5-HT- K .2000 .1A receptoragonist,fiesinoxan,on the extracellulnaorradrenalinelevelin thehippocampus and on thelocomotoractivityof rats. Brain Bes, 858(2) : 393-401.
Soderpalm B,Lundin B,Hjorth S B,withanxiolyticdrugs VI .1989 .ing of drugs interactingwith serotonin receptor subtypes. JPharma Exp Ther, 250 : 809-17.